ERBB2 and breast cancer: However, when the moderately sensitive SKBR3 cells were included in the analysis, we did not observe a consistent pattern for the atorvastatin-induced dysregulation of LDLR transcript expression within the entire group of sensitive BC cells, although their belonging to two distinct clinical subtypes, HER2+ and triple negative-subtype respectively36,37, may be a plausible explanation for such variable response to treatment.